Registration Number
0224U002953,
0121U110083
, R & D reports
Title
Optimize the diagnosis and treatment of patients with non-Hodgkin's lymphoma of T-cell origin.
popup.stage_title
Head
Kriachok Iryna A.,
Registration Date
18-03-2024
Organization
National Cancer Institute
popup.description2
Object of study - non-Hodgkin's lymphomas, immunohistochemical and molecular genetic factors of the course of the disease. Aim of the study: to improve treatment results for patients with T-cell lymphomas by developing individualized therapeutic approaches. Research methods and equipment: morphological, immunohistochemical, stastistical methods. A nationwide registry of T-cell lymphomas was created at the National Cancer Institute, including 756 patients with newly diagnosed lymphoma. Data analysis of 98 patients with primary T-cell lymphomas was performed. Patients were stratified into four groups according to the type of TCL: 1st group (A) - leukemic (n=18), 2nd group (B) - nodal T-cell lymphomas (n=58); 3rd group (C) – cutaneous T-cell lymphomas (n=15), 4th group (D) - extranodal T-cell lymphomas (n=7). All patients received treatment depending on the type of T-cell lymphoma: SMILE or HyperCVAD with or without auto/allo-HSCT for the first group, CHOP-like regimens for the second group, and PUVA-therapy, interferon, and methotrexate for the third group. The overall response to therapy (OR) was 59,18% (n=58), including partial and complete responses. The 18-month relapse-free survival (RFS) was 49%, and the 18-month overall survival was 63,8% Statistical analysis revealed that the 18-month PFS for group B was higher compared to groups A, C and D (72,36%, 24,93%, 38,75% and 27,77% respectively). Similarly, the 2-year overall survival (OS) was also higher for group B compared to groups A, C and D (74,81 %, 27,32 %, 47,23% and 30,0 % respectively). Unfavorable prognostic factors included bone marrow involvement (p = 0.03) and Ki-67 expression > 65% (p=0.006). 38 primary cases of peripheral T-cell lymphoma were treated using the CHOP and CHOEP chemotherapy regimens. Patients were stratified based on the negative prognostic factor Ki-67.
Product Description
popup.authors
Aleksyk Olena M.
Ashykhmin Andrii V.
Holovko Tetiana S.
Lavryk Halyna V.
Tytorenko Iryna B.
popup.nrat_date
2024-03-18
